Capitolis UK Approved to Operate an Organized Trading Facility (OTF) by the FCA March 31, 2026 Approval unlocks more optimization opportunities and efficiencies for clients and network
CapVest Completes Majority Acquisition of Stada March 31, 2026 CapVest Partners LLP (“CapVest”), a leading global investment firm, today announces the completion of its acquisition of the majority stake in STADA Arzneimittel AG (“STADA” or the “Company”), a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty Pharmaceuticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331987319/en/ Building on [...]
Softr Unveils an AI-Native Platform, Ushering in a New Era of Business Software Creation Without Code March 31, 2026 New AI-platform enables non-tech teams to build fully functional, secure applications for real business operations, not just prototypes
iBase-t Announces Strategic Growth Investment from TA to Accelerate AI-Powered Digital Manufacturing and MRO Transformation in Aerospace & Defense March 31, 2026 iBase-t, a leading provider of Manufacturing Operations Management software for aerospace and defense manufacturers, today announced a strategic growth investment from TA Associates (TA), a global growth private equity firm. The investment will support iBase-t’s continued product innovation and global expansion as global aerospace and defense manufacturers scale production, modernize sustainment operations, and accelerate adoption [...]
ECCEUKCH: The First Year of Activities to Promote European Extra Virgin Olive Oil in the UK and Switzerland Comes to a Close March 31, 2026 The first year of ECCEUKCH – The Excellence of European Olive Growing in the UK and Switzerland, the three-year information and promotion programme dedicated to high-quality European extra virgin olive oil, co-financed by the European Union under Regulation (EU) No 1144/2014, has come to an end. Promoted by the Tuscan Association of Olive Growers OL.MA. [...]
Fresha Becomes the Software Infrastructure of Choice for Multi-location Selfcare Businesses as Enterprise Growth Surges March 31, 2026 Fresha, the top-rated AI-powered booking platform for beauty and wellness, is witnessing significant enterprise growth as multi-location and large-team businesses increasingly choose Fresha to manage and scale their operations. Leading well-established brands, including Menspire, Ted’s Grooming Room, Gould Barbers, Masaj, Adams Barbers, The Art of Nails, and more, are among a growing cohort of enterprise [...]
Thermochemical Energy Storage Leader Redoxblox Rebrands as Tempo March 31, 2026 Breaking the heat barrier: Tempo advances towards commercial rollout of continuously delivered electrified industrial heat at up to 1,200°C
Allshares Acquires Technology Company Amalia to Accelerate Innovation in Ownership and Incentive Management March 31, 2026 Allshares, a global equity and ownership management platform, today announced the acquisition of Amalia, a France-based company specializing in sales commission and performance management software. The acquisition strengthens Allshares’ platform, adding a sophisticated, rules-based engine that expands and enhances its end-to-end ownership offering. Founded in 2020, Amalia was built technology-first. Its software is centered on [...]
Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets March 31, 2026 Revenues of €1.8 billion (-4% versus PY) driven by solid performance across key therapeutic areas and global markets, partially offset by Ocaliva® withdrawal impact. Adjusted EBITDA2 of €350 million (-18% versus PY) underpinned by streamlined operational efficiencies and operating model evolution. Like-for-like Revenues up 7%, and EBITDA up 20%, adjusted for voluntarily withdrawal of Ocaliva® from US market. Marketing application under EMA review for the use of Jyseleca® in a new indication of axial spondyloarthritis (axSpA), a chronic inflammatory arthritis, to address unmet patient needs, submitted following the reporting period. Following the reporting period, agreement with GSK plc for worldwide exclusive rights to develop, manufacture and commercialise linerixibat; subsequently granted FDA approval for the US market (March 2026).
AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial March 31, 2026 Early biomarker and safety data show encouraging signals with plans to present additional data in 2H 2026 AviadoBio secures strategic investment from The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) through their Treat FTD Fund to support ASPIRE-FTD Trial AviadoBio regains full rights to AVB-101 gene therapy program
